Biopeople at a Glance

Transcription

1 Biopeople at a Glance Future Directions in Regulatory Science Copenhagen 21 April 2016 Per Spindler, Director

2 Welcome to Biopeople Biopeople, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark Cluster organisation since Since 2010 part of the national innovation programme by the Ministry of Higher Education and Science Per Spindler, Director (2005-) Randi Krogsgaard, Communication Manager (2013-) Elias Zafirakos, Manager (2005-) Niels Westergaard, Manager (2011-) Jette Claville, Secretary (2010-)

3 The World's Best Business Environment among the most innovative in the world A Strong Healthcare Industry World-Class Research Standards Highly Qualified Labour Tradition for Public-Private Partnerships Unique Framework Conditions for Medical Research and Clinical Trials Total R&D personnel nationwide per capita, full-time work equivalent (FTE) per 1,000 people. The higher the score, the better. Source: IMD 2015 Efficient Public Authorities Expertise in Design, Engineering and Clinical Competences World Leader in IT Infrastructure

4 Top 3 reasons for placing pharma - biotech business activities in Denmark Largest percentage of patents in biotechnology in the World (Scientific American 2014) Ranked as the third best country in the world after the United States and Singapore for development of biotechnology (Scientific American 2014) Largest commercial drug development pipeline in Europe (Ernst & Young, 2014) Ernst & Young 2004

5 The case of The Danish Pharmaceutical Industry -Employs approximately 20,000 persons in Denmark - forms the basis of approximately 70,000 indirect jobs -Pays DKK 16bn in tax annually -Exports medicinal products for DKK 84,5bn in about 12,6 percent of the total Danish export Productivity measured on the value added per employee is approximately 2.6 times as large as the business community as a whole Invests every year in more than DKK 10,5 bn in research and development of new medicinal products - undisputed the largest private research area nationally Source:

6 The Danish industry developed from the big four

7 ... and newer biotech companies

8 Danish Life Science grows through innovation and collaboration... Biopeople facilitates confidence-building interpersonal relations. This is to fulfil the needs of our stakeholders for strengthening innovation through cross disciplinary and international partnerships. We focus on Creating inspiring meeting places for companies and people who want to share ideas Facilitating cross disciplinary collaboration and partnership bringing smaller companies, public/private synergy and internationalization into the spotlight Supporting the development of professional competences within especially internationalization, innovation and foresight

9 Biopeople s partnership case embeds all relevant national stakeholders to change the health care and biopharma paradigm shift Research and education Intermediates, e.g. associations and networks Marketing and communication Government and public administration Businesses, industry and service providers Biopeople is open for businesses (industry & service) and organizations: Free of charge

10 Strategy development in Biopeople The silos and broad priorities The two priority themes Personalised / precision medicines health care paradigm shift Life Science SMEs & academia ecosystem & new business models

11 Biopeople successes are aligned to strategic priorities towards SMEs, academia and personalised medicine Biomarkers, Companion Diagnostics Patient Empowerment... SME VOUCHERS & INTERNATIONALISATION BIOMARKERS & REGULATORY PATIENT TRAINING & EMPOWERMENT

12 Our response to the industry changes in health care: boosting personalised medicine and services and ensuring Danish companies being part of the value chain......enabling change to personalised medicine and services by advancing biomarkers and companion diagnostics

13 Our response to the industry changes in health care: boosting personalised medicine and services and ensuring Danish companies being part of the value chain......enabling change to personalised medicine and services by boosting international collaborations of companies and new business models 34 DK Voucher Programmes in the IN2LS

14 Regulatory Science Biopeople focus on the health care paradigm shift embedded in personalised medicine Regulatory science plays an important part of this transition: Instrumental in DIA and the TIRS driver of internationalisation and publications Established the Copenhagen Centre for Regulatory Science driver of academic contributions and interactions Key partner in IMI projects Patient training and engagement driver of stakeholder changes Many meetings, workshops etc. re. regulatory driver of new networks and topics